OVERVIEW

8th Annual Shaping the Management of Parkinson’s Disease: Debating Current Controversies and Discussing Recent Advances is organized by Cleveland Clinic Center for Continuing Education, Parkinson Study Group (PSG) and will be held from Jan 23 - 24, 2021.

Accreditation:
The Cleveland Clinic Foundation Center for Continuing Education designates this internet live activity for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Overview:
Innovations and advances in the field of PD - including evaluation, treatment, and prevention - continue to occur at a rapid pace, challenging both specialists and generalists to stay abreast of the changes, creating gaps in knowledge, competence, and practice among health care providers. In many cases, the data are not clear regarding the clinical implications. In turn, this creates a pressing need for educational activities focused on providing updates and critical analyses of both the pros and cons of the most recent advances in the care of patients with PD.

Learning Objectives:
After completing this activity, the participant will be able to do the following:
• List the most recent insights from studies investigating the role of genetic targets in disease- modifying therapies for Parkinson disease.
• Discuss how COVID-19 has promoted telemedicine for follow-up care of patients with Parkinson disease as well as its impact on clinical trial design.
• Summarize the evidence supporting the efficacy of behavioral and nonmotor therapies for Parkinson disease.
• Critically assess the outcomes and issues when comparing closed-loop technology against directional leads for deep brain stimulation.
• Describe the available neuropsychological tests for detecting mild cognitive impairment in Parkinson disease and discuss the best timing of their use.
• List the options for short-acting rescue therapies in Parkinson disease and their potential use as on-demand therapy.
• Discuss the accuracy of the scale for measuring motor fluctuations in Parkinson disease in relation to its use as an outcome measure in symptomatic trials.